The Weather Network Introduces Allergy Outlook Report in Partnership with FLONASE® Allergy Relief

Seasonal allergy sufferers now have a new resource for pollen, mold and air quality information

Oakville, February 22, 2017 – The Weather Network and French counterpart MétéoMédia announced today the launch of the Allergy Outlook in partnership with FLONASE® Allergy Relief, recently launched in Canada as the first and only non-prescription nasal spray indicated for relief of both eye-related and nasal allergy symptoms.1,2 Launching initially in British Columbia, where seasonal allergies typically begin in February, the Allergy Outlook will be fully available across Canada in March, just as seasonal allergies are beginning to flourish with the spring weather. For the 25 per cent of Canadians suffering from seasonal allergies,3 the Allergy Outlook provides valuable and timely information on mold, pollen and air quality levels.

“The Allergy Outlook report provides allergy sufferers with the information they need to know in one convenient place, while at home or on the go,” said Martin Belanger, Director of Content and Product Management with The Weather Network and MétéoMédia. “The visual graphs and detailed legend are comprehensive and will help our users get the most out of their day.”

Weather plays an important role in how seasonal allergies manifest, and weather patterns can affect allergens like pollen and mold that trigger allergy symptoms. For this reason, FLONASE® Allergy Relief and The Weather Network have teamed up to help Canadians – a fitting collaboration that will educate allergy sufferers about the impact of changing weather patterns and help them manage their symptoms.

The Allergy Outlook report, available at, and, delivers a visual look at the risk of pollen, mold and air quality information every day for nearly 11,000 locations across Canada. To help Canadians understand their risks for allergy symptoms, air quality indicators will be available for the current day with a rating of low, medium or high. Pollen and mold levels will include ratings for both the current day and up to 48 hours in advance with ratings of low, medium, high and very high.

“We know that Canadian allergy sufferers continue to be frustrated by their allergy symptoms. A daily report providing information that allows allergy sufferers to successfully plan their days and do more of the things they enjoy is a great way to help them,” said Babita Bhattal, Director of Marketing, GSK Consumer Healthcare. “FLONASE® Allergy Relief is partnering with The Weather Network and MétéoMédia to bring Canadians a way to really get ahead of their allergies.”

The Weather Network & MétéoMédia are also releasing educational and informative articles throughout the season regarding allergies and how weather can, at times, affect pollen, mold or air quality levels in the atmosphere.

Canadians can consult, and on desktop and mobile sites to access the Allergy Outlook report and learn more about seasonal allergies.

About FLONASE® Allergy Relief

FLONASE® Allergy Relief is the first and only non-prescription nasal spray in Canada indicated for relief of both eye-related and nasal allergy symptoms caused by seasonal and year-round allergens, including pollen, mold, dust and pets.4 It provides 24 hour, non-drowsy allergy relief of: sneezing, itchy nose and throat, runny nose and itchy, watery eyes, nasal congestion and sinus pain and pressure.5, 6 FLONASE® Allergy Relief is available at local pharmacies for adults 18 years and older.

About Pelmorex Media Inc.

Celebrating 27 years, Pelmorex Media Inc. is the parent company of The Weather Network, MétéoMédia, and Pelmorex operates in North America, Europe, LATAM, India and Australia. The Weather Network and its French counterpart MétéoMédia are Canada’s most popular weather and information services on TV, web and mobile apps. Eltiempo is Spain’s leading multi-platform weather information provider. Pelmorex also operates Canada’s National Alerting Aggregation and Dissemination System which aggregates and distributes emergency alerts issued by authorized government agencies.

About GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline Consumer Healthcare is one of the world’s largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include Voltaren Emulgel®, Aquafresh®, Sensodyne®, and TUMS® – which are trademarks owned by and/or licensed to GlaxoSmithKline Group of Companies. These brands are successful in over 100 countries around the world because they all show our passion for quality, guaranteed by science. They are inspired by the real wants and needs of the millions of people who walk into pharmacies, supermarkets, market stalls and go on-line all over the world every day, and choose us first.

Our goal is to build a global, growing business we call a Fast Moving Consumer Healthcare (FMCH) company, dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.

About GlaxoSmithKline

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit:

For further information, please contact:

Deanna Ghandour

The Weather Network

905-829-1159 ext. 1358,

Marsha Rosenberg



Joanmarie Goddard

GSK Consumer Healthcare



1 Flonase® Allergy Relief Product Monograph. GSKCH. Aug 26, 2016.

2 Nasocort® Allergy 24HR Product Monograph. Sanofi-aventis Canada Inc. December 2, 2013.

3 Keith P, et al. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol. 2012; 8(1): 7.

4 Flonase® Allergy Relief Product Monograph. GSKCH. Aug 26, 2016.

5 Flonase® Allergy Relief Product Monograph. GSKCH. Aug 26, 2016.

6 Nasocort® Allergy 24HR Product Monograph. Sanofi-aventis Canada Inc. December 2, 2013.

7 Flonase® Allergy Relief Product Monograph. GSKCH. Aug 26, 2016.